MELISSA NURRENBERN: Open Payments
NPI 1538936984 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,545 in 68 payments from 18 companies in 2025. Trend: 2023 $139 · 2024 $1,423 · 2025 $1,545
Food & beverage: $1,545
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 9 | $312 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $221 |
| ABBVIE INC. | 12 | $221 |
| Janssen Biotech, Inc. | 8 | $164 |
| GENZYME CORPORATION | 4 | $103 |
| PFIZER INC. | 5 | $100 |
| QOL Medical, LLC | 3 | $56 |
| Ardelyx, Inc. | 2 | $53 |
| Phathom Pharmaceuticals, Inc. | 3 | $51 |
| Gilead Sciences, Inc. | 2 | $42 |
Products named: REZDIFFRA, RINVOQ, TREMFYA, ENTYVIO, DUPIXENT, VELSIPITY, Sucraid, EOHILIA.
Industry payments across IN — which companies pay providers there.
